Gilead Sciences agreed to acquire Ouro Medicines in a front-loaded deal that secures OM336 (gamgertamig), a BCMA×CD3 T‑cell engager in Phase I/II for antibody‑mediated autoimmune diseases. The acquisition includes an advanced discussion to partner with Galapagos on co-development and cost‑sharing, shifting Ouro’s assets and staff into a joint operating plan. Gilead positioned the buyout as strategic expansion of its inflammation and cell‑therapy portfolio, citing Fast Track and Orphan designations for OM336 and plans for registrational work starting in 2027. The deal combines an up‑front cash commitment with contingent milestones and royalty arrangements that reflect a high‑risk, high‑reward bet on TCEs as immune‑reset therapies.